Correct Answer: C. Tolvaptan
Tolvaptan is a selective V2-receptor antagonist (vaptans class) that represents the modern pharmacological gold standard for chronic SIADH management. Unlike older agents, tolvaptan directly antagonizes vasopressin at the collecting duct, promoting aquaresis (free water excretion without electrolyte loss), thereby correcting hyponatremia while maintaining serum osmolality. In chronic SIADH, tolvaptan allows gradual sodium correction (8–10 mEq/L per 24 hours) with lower risk of osmotic demyelination syndrome compared to hypertonic saline. It is particularly valuable in SIADH secondary to malignancy, CNS disorders, or pulmonary disease—common presentations in Indian clinical practice. The drug is administered orally (7.5–60 mg daily) with dose titration based on serum sodium response, making it ideal for long-term outpatient management. Unlike fluid restriction (which is poorly tolerated and non-specific) or demeclocycline (which requires days to weeks for effect and carries nephrotoxicity risk), tolvaptan provides rapid, predictable sodium correction. Current international guidelines (including those adapted in Indian practice) recommend vaptans as first-line pharmacotherapy for symptomatic or severe chronic SIADH when fluid restriction fails.
Why the other options are wrong
A. Demeclocycline — Demeclocycline (a tetracycline) induces nephrogenic diabetes insipidus and was historically used for SIADH, but it is now considered second-line. It requires 5–7 days to achieve effect, carries risk of photosensitivity and renal toxicity (especially in Indian patients with underlying CKD), and is less predictable than vaptans. It is reserved only when vaptans are unavailable or contraindicated. B. Fludrocortisone — Fludrocortisone is a mineralocorticoid that increases sodium reabsorption in the collecting duct and is used in SIADH only when hyponatremia is accompanied by hypovolemia or adrenal insufficiency. In euvolemic or hypervolemic SIADH (the majority of cases), fludrocortisone worsens fluid retention and hyponatremia. It is not first-line for chronic SIADH management. D. Reducing fluid intake to <500 ml per day — Severe fluid restriction (<500 mL/day) is the initial non-pharmacological approach for mild-to-moderate SIADH, but it is poorly tolerated long-term, leads to patient non-compliance, and does not address the underlying pathophysiology. For chronic SIADH requiring sustained treatment, pharmacotherapy with vaptans is superior and more practical in Indian outpatient settings.
High-Yield Facts
- Vaptans (V2-receptor antagonists) are first-line pharmacotherapy for chronic symptomatic SIADH, promoting aquaresis and gradual sodium correction.
- Tolvaptan dosing: 7.5–60 mg orally daily, titrated to achieve 8–10 mEq/L sodium rise per 24 hours to avoid osmotic demyelination.
- Demeclocycline requires 5–7 days onset, carries nephrotoxicity risk, and is now second-line; reserved when vaptans unavailable.
- Fludrocortisone is used only in hypovolemic SIADH with concurrent adrenal insufficiency; worsens euvolemic/hypervolemic SIADH.
- Fluid restriction (<500–800 mL/day) is initial non-pharmacological management but poorly tolerated; pharmacotherapy preferred for chronic cases.
Mnemonics
SIADH Treatment Ladder (Chronic) Fluid restriction → Demeclocycline → Vaptans (Tolvaptan). Start conservative; escalate if non-compliant or severe. Vaptans = modern gold standard. Vaptan Mechanism: 'AQUA-resis' V2-antagonist → blocks ADH → AQUeous (free water) excretion without sodium loss = Aquaresis. Corrects hyponatremia while preserving osmolality.
NBE Trap
NBE may pair demeclocycline with "chronic SIADH" to test whether students confuse historical agents with modern first-line therapy. The trap exploits older textbook emphasis on demeclocycline without reflecting current guideline shifts toward vaptans in Indian practice.
Clinical Pearl
In Indian tertiary centres, tolvaptan has become the preferred agent for malignancy-associated SIADH (common in lung cancer patients) and CNS-SIADH (post-meningitis, head trauma), allowing safe outpatient sodium correction without hospitalization or invasive monitoring—a practical advantage in resource-limited settings.
_Reference: KD Tripathi Pharmacology Ch. 34 (Endocrine Drugs); Harrison Principles of Internal Medicine Ch. 429 (Hyponatremia & SIADH)_